PL3271349T3 - Pochodne benzimidazolu jako inhibitory bromodomen - Google Patents

Pochodne benzimidazolu jako inhibitory bromodomen

Info

Publication number
PL3271349T3
PL3271349T3 PL16710214T PL16710214T PL3271349T3 PL 3271349 T3 PL3271349 T3 PL 3271349T3 PL 16710214 T PL16710214 T PL 16710214T PL 16710214 T PL16710214 T PL 16710214T PL 3271349 T3 PL3271349 T3 PL 3271349T3
Authority
PL
Poland
Prior art keywords
benzimidazole derivatives
bromodomain inhibitors
bromodomain
inhibitors
benzimidazole
Prior art date
Application number
PL16710214T
Other languages
English (en)
Inventor
Rino Antonio Bit
John Alexander Brown
Philip G Humphreys
Katherine Louise Jones
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PL3271349T3 publication Critical patent/PL3271349T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
PL16710214T 2015-03-19 2016-03-17 Pochodne benzimidazolu jako inhibitory bromodomen PL3271349T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1504689.9A GB201504689D0 (en) 2015-03-19 2015-03-19 Chemical compounds
EP16710214.4A EP3271349B1 (en) 2015-03-19 2016-03-17 Benzimidazole derivatives as bromodomain inhibitors
PCT/EP2016/055792 WO2016146738A1 (en) 2015-03-19 2016-03-17 Benzimidazole derivatives as bromodomain inhibitors

Publications (1)

Publication Number Publication Date
PL3271349T3 true PL3271349T3 (pl) 2019-10-31

Family

ID=53052091

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16710214T PL3271349T3 (pl) 2015-03-19 2016-03-17 Pochodne benzimidazolu jako inhibitory bromodomen

Country Status (36)

Country Link
US (2) US10442786B2 (pl)
EP (2) EP3549939A1 (pl)
JP (1) JP6419990B2 (pl)
KR (1) KR102072850B1 (pl)
CN (1) CN107635989B (pl)
AR (1) AR103934A1 (pl)
AU (1) AU2016232217B2 (pl)
BR (1) BR112017019779B1 (pl)
CA (1) CA2979504C (pl)
CL (1) CL2017002332A1 (pl)
CO (1) CO2017009992A2 (pl)
CR (1) CR20170430A (pl)
CY (1) CY1121855T1 (pl)
DK (1) DK3271349T3 (pl)
DO (1) DOP2017000213A (pl)
EA (1) EA033594B1 (pl)
ES (1) ES2735417T3 (pl)
GB (1) GB201504689D0 (pl)
HR (1) HRP20191186T1 (pl)
HU (1) HUE044414T2 (pl)
IL (1) IL254318B (pl)
LT (1) LT3271349T (pl)
MA (2) MA46981A (pl)
ME (1) ME03485B (pl)
MX (1) MX2017012023A (pl)
PE (1) PE20180032A1 (pl)
PH (1) PH12017501620A1 (pl)
PL (1) PL3271349T3 (pl)
PT (1) PT3271349T (pl)
RS (1) RS59056B1 (pl)
SG (1) SG11201707356QA (pl)
SI (1) SI3271349T1 (pl)
SM (1) SMT201900428T1 (pl)
TW (1) TW201706257A (pl)
UY (1) UY36589A (pl)
WO (1) WO2016146738A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
HK1256753A1 (zh) 2015-08-11 2019-10-04 Neomed Institute 芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
CN114605387A (zh) 2015-08-12 2022-06-10 埃皮吉纳提克斯股份有限公司 取代的苯并咪唑、它们的制备和它们作为药物的用途
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
GB201614940D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614939D0 (en) 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate
GB201614934D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
US10617680B2 (en) * 2017-04-18 2020-04-14 Celgene Quanticel Research, Inc. Therapeutic compounds
CN109280046B (zh) * 2017-07-21 2021-02-02 浙江海正药业股份有限公司 苯并咪唑类衍生物及其制备方法及其在医药上的用途
WO2019154329A1 (zh) * 2018-02-06 2019-08-15 上海海和药物研究开发有限公司 具有bet抑制活性的化合物及其制备方法和用途
CN109369432B (zh) * 2018-11-02 2021-06-25 永农生物科学有限公司 (s)-4-氯-2-氨基丁酸酯的制备方法
JP2022053557A (ja) * 2019-02-08 2022-04-06 マルホ株式会社 ピリドン誘導体
EP3937936A4 (en) * 2019-03-15 2022-12-28 Forma Therapeutics, Inc. INHIBITION OF CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB)
WO2020219168A1 (en) * 2019-04-24 2020-10-29 Convergene, Llc Small molecule bromodomain inhibitors and uses thereof
WO2020223370A1 (en) * 2019-04-29 2020-11-05 The Board Of Regents Of The University Of Texas System Compositions and methods for treating schistosoma infections
CN116217416A (zh) * 2022-12-31 2023-06-06 黄淮学院 一种苯并咪唑类药物中间体3-硝基-4-乙基氨基苯甲醇的制备方法
IL324913A (en) * 2023-05-30 2026-01-01 16380026 Canada Inc Cyp26b1 inhibitor compounds and methods of use thereof
CN119219631B (zh) * 2024-12-04 2025-04-18 山东大学 一种bet蛋白溴结构域bd1选择性共价抑制剂及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
ATE478067T1 (de) 2006-03-31 2010-09-15 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
EP2493310A4 (en) * 2009-10-27 2014-03-12 Glaxosmithkline Llc BENZIMIDAZOLES AS INHIBITORS OF ACID GRAS SYNTHASE
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
KR101594002B1 (ko) 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Pi3 키나제 억제제로서의 벤즈이미다졸 유도체
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
CN105073747B (zh) 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類
TWI527811B (zh) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
CN105473581B (zh) * 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US9428515B2 (en) * 2014-05-09 2016-08-30 Boehringer Ingelheim International Gmbh Benzimidazole derivatives
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201504694D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate

Also Published As

Publication number Publication date
LT3271349T (lt) 2019-07-10
CA2979504A1 (en) 2016-09-22
KR102072850B1 (ko) 2020-02-03
UY36589A (es) 2016-10-31
SG11201707356QA (en) 2017-10-30
PT3271349T (pt) 2019-08-19
CN107635989B (zh) 2020-12-08
US11053212B2 (en) 2021-07-06
CL2017002332A1 (es) 2018-03-16
EA033594B1 (ru) 2019-11-07
HUE044414T2 (hu) 2019-10-28
IL254318B (en) 2019-08-29
ME03485B (me) 2020-01-20
BR112017019779B1 (pt) 2023-10-03
DOP2017000213A (es) 2017-10-15
CO2017009992A2 (es) 2018-01-05
SI3271349T1 (sl) 2019-08-30
CR20170430A (es) 2017-11-08
US20180044317A1 (en) 2018-02-15
US20200039953A1 (en) 2020-02-06
AU2016232217A1 (en) 2017-10-12
SMT201900428T1 (it) 2019-09-09
TW201706257A (zh) 2017-02-16
WO2016146738A1 (en) 2016-09-22
KR20170129871A (ko) 2017-11-27
MA41778A (fr) 2018-01-24
PE20180032A1 (es) 2018-01-09
JP2018507903A (ja) 2018-03-22
HRP20191186T1 (hr) 2019-10-04
IL254318A0 (en) 2017-11-30
MA46981A (fr) 2019-10-09
GB201504689D0 (en) 2015-05-06
CN107635989A (zh) 2018-01-26
RS59056B1 (sr) 2019-08-30
CA2979504C (en) 2023-10-10
DK3271349T3 (da) 2019-08-05
EP3549939A1 (en) 2019-10-09
AU2016232217B2 (en) 2019-04-04
JP6419990B2 (ja) 2018-11-07
MX2017012023A (es) 2018-01-30
ES2735417T3 (es) 2019-12-18
AR103934A1 (es) 2017-06-14
EA201791973A1 (ru) 2018-07-31
BR112017019779A2 (en) 2018-05-22
CY1121855T1 (el) 2020-07-31
EP3271349A1 (en) 2018-01-24
EP3271349B1 (en) 2019-05-15
PH12017501620A1 (en) 2018-02-12
US10442786B2 (en) 2019-10-15

Similar Documents

Publication Publication Date Title
IL254318A0 (en) History of benzaimidazoles as bromodomain inhibitors
IL255006A0 (en) Bromodomain inhibitors
ZA201800826B (en) Substituted oxopyridine derivatives
IL256808A (en) Heteroaryl derivatives as parp inhibitors
SG11201509220XA (en) Benzimidazole derivatives as bromodomain inhibitors
IL251784A0 (en) Bromodomain inhibitors
IL246140A0 (en) History of bicyclic heterocyclics as bromodomain repressors
PL3218378T3 (pl) Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
PT3442972T (pt) Inibidores de bromodomínio
IL253381A0 (en) History of h9-pyrrolo-dipyridine
ZA201700883B (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
AP2016009661A0 (en) Quinolizinone derivatives as pi3k inhibitors
IL251005B (en) Pyrido-oxazinone derivatives
TH1501005855A (th) อนุพันธ์เบนซิมิดาโซโลนที่เป็นสารยับยั้งโบรโมโดเมน(Benzimidazolone Derivatives as Bromodomain Inhibitors)
TH1501006739A (th) อนุพันธ์ของเบนซิมิดาโซลที่เป็นสารยับยั้งโบรโมโดเมน